Category: JCN Newswire

TOKYO and CAMBRIDGE, Mass., July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB)announced today that new data presented at the Alzheimer’s Association International Conference®(AAIC®) 2026 in London support that the LEQEMBI® (lecanemab) subcutaneous autoinjector (SC-AI)formulation offers efficacy and safety comparable to intravenous (IV) administration for people with early Alzheimer’s disease (AD). The data was featured during the “Lecanemab Subcutaneous Formulation in Early Alzheimer’s Disease: Emerging Clinical Evidence and Practical Use Considerations” Developing Topics Session #1-32-FRS-C.AD is a chronic, progressive disease that requires ongoing treatment. LEQEMBI is an early AD treatment that targets the underlying pathology of the disease, helping to slow cognitive decline and loss of daily functioning. The lecanemab subcutaneous auto-injector (SC-AI) was developed to provide a more convenient alternative to intravenous (IV) dosing from the initiation of treatment.Key FindingsThis session presented data from the lecanemab SC-AI development program in early Alzheimer’s disease, including pharmacokinetic (PK), pharmacodynamic (PD), efficacy, safety and real-world patient and care partner experience findings. Results showed that once-weekly 500 mg SC-AI achieved drug exposure similar to the approved intravenous (IV) initiation regimen (10 mg/kg every two weeks), supporting the expectation of similar clinical efficacy and safety, independent of the route of administration. The subcutaneous dosing option may offer a convenient at-home alternative to IV infusion which could support access and delivery of care across healthcare settings.Data ShowedBioequivalence Achieved: Once-weekly 500 mg SC-AI demonstrated bioequivalence to the IV initiation regimen (10 mg/kg every two weeks), with an exposure ratio of 104% (90% confidence interval [CI]: 99.1%–109%). Exposure remained consistent across body weight quartiles, demonstrating a stable pharmacokinetic profile in a broad patient population.Efficacy Driven by Exposure, Not Route of Administration: Amyloid removal measured by amyloid PET, clinical efficacy measured by CDR-SB, and the incidence of ARIA-E were driven by lecanemab exposure rather than route of administration. The 500 mg SC-AI initiation regimen achieved exposure comparable to the IV initiation regimen, supporting the expectation of acomparable efficacy and safety profile despite the different route of administration.Consistent Results Across Patient Populations: The 500 mg SC-AI initiation regimen demonstrated consistent exposure, amyloid clearance as measured by amyloid PET, clinical efficacy and safety across body weight groups. In addition, amyloid clearance and clinical outcomes were not meaningfully affected by body weight, supporting the appropriateness of a fixed-dose regimen.Flexible switching between IV and SC administration: Patients may also switch from IV to SC administration, or vice versa, and if a dose is missed patients can take it the next day or up to day six providing greater convenience and flexibility in LEQEMBI administration.Safety Profile Aligned of SC LEQEMBIOverall safety profile of SC-AI was generally consistent with that observed for the IV formulation.Incidence of ARIA-E with the 500 mg SC-AI initiation regimen was predicted to be similar to that observed with the IV initiation regimen. Injection-related reactions were observed with subcutaneous LEQEMBI, most of which were localized, while systemic reactions were less frequently observed.The incidence of anti-drug antibodies (ADA) was low, at 1.4% in the 500 mg SC-AI group. No neutralizing antibodies were observed, confirming that the low immunogenicity profile was maintained with the SC-AI formulation.Clinical Trial Perspectives and Real-World Evidence: Sustained Clinical Benefit with SC-AIData from two U.S. Alzheimer’s treatment centers (Alzheimer’s Research and Treatment Center,and First Choice Neurology and Visionary Investigators Network) provide early insight into clinical trial and real-world use of subcutaneous LEQEMBI:At Alzheimer’s Research and Treatment Center, 28 patients receiving SC administration demonstrated slower cognitive decline as measured by CDR-SB over 36 months relative to a matched Alzheimer’s Disease Neuroimaging Initiative (ADNI) natural history cohort. The cohort included 25 patients newly initiated on SC administration and 3 patients who transitioned from IV administration.In a separate case series from First Choice Neurology and Visionary Investigators Network, 10 of 11 evaluable patients (91%) showed improvement or remained stable on MMSE compared with baseline before maintenance therapy. At this center, patients who had received maintenance therapy with SC administration for at least 6 months were included in the analysis.Patient and care partner surveys in these two sites demonstrated high satisfaction with subcutaneous LEQEMBI administration, with satisfaction rates ranging from 75% to 97%, convenience ratings from 83% to 97%, and willingness to recommend treatment ranging from 92% to 100%.Results presented in this session further reinforce the importance of early and continuous treatment, highlighting how LEQEMBI SC initiation and maintenance administration provides greater optionality for long-term disease management. Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisaiand Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 797 487 9419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1201-753-1945Libby_Holman@eisai.comBiogen Inc.Madeleine Shin+1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Biogen Inc.Tim Power+1-781-464-2442IR@biogen.comFor more information: https://www.eisai.com/news/2026/pdf/enews202638pdf.pdf Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

DALLAS, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi Digital Services today announced it has partnered with ServiceNow (NYSE: NOW), the AI control tower for business reinvention, to strengthen reliable and efficient management of mission critical infrastructure. Through this collaboration, the companies will advance Hitachi Intelligent Infrastructure Monitoring (HIIM) — an AI-driven solution that provides real-time monitoring and remote inspection while enabling a coordinated response across complex operations environments. As part of the broader partnership ecosystem, this collaboration leverages Hitachi Digital Services’ deep operational technology(OT) domain knowledge along with its physical AI and systems integration expertise to help customers connect operational data and enterprise workflows on the ServiceNow AI Platform, enabling teams to act on insights at scale.The combined HIIM and ServiceNow platform supports the vision of HMAX by Hitachi for intelligent solutions that safeguard and enable efficient operations of critical infrastructure. HMAX is a suite of next-generation solutions that brings the power of AI to social infrastructure with capabilities that optimize planning, prediction, and prevention via combined asset intelligence, digital services, and expert support for lifetime infrastructure management. Collectively, such innovations support Hitachi’s mission of tackling the most complex social infrastructure challenges to maximize outcomes and value for clients and society.Mission-critical infrastructure operators across the energy, mobility and manufacturing sectors face increasing pressure to maintain safety, reliability, and performance amid workforce constraints and operational demands. Operator requirements are made even more challenging when considering the often-disparate systems and subsequent siloed data sources needed to inform necessary, prompt decisions. Further, many organizations are unable to put operations data into action consistently across teams and systems in real time.“The organizations winning with AI aren't the ones with the most data. They're the ones who can act on it, across teams, in real time, with governance built in. Hitachi Digital Services brings the domain depth to understand what matters in mission-critical environments. ServiceNow provides the platform to turn that expertise into autonomous action, at scale," said Chris Bedi, ServiceNow chief customer officer and enterprise AI advisor. “For joint customers in energy, manufacturing, and mobility, closing that gap means moving from reactive response to autonomous resolution. As a result, our customers can expect to reduce risk, protect workers, and keep operations running.”A manufacturer-agnostic technology, HIIM integrates data sourced from video, thermal imaging, IoT sensors, and advanced analytics to deliver continuous visibility into infrastructure health. When combined with ServiceNow Workflow Data Fabric, analytics, and AI-driven workflows, HIIM extends beyond data visibility to drive automated enterprise-wide action that allows operations to: Compile data from multiple fragmented sources in real timeConvert compiled data into automated workflowsDetect, prioritize, and respond to issues proactively and with speedSeamlessly connect operations and enterprise teams to accelerate resolution and reduce risk“Hitachi Digital Services and the ServiceNow AI Platform combine industry depth with AI-powered enterprise workflow automation to further eliminate the disconnect between field operations and enterprise systems. The outcome is a real-time, connected operating model that turns insight into action at scale. In mission-critical environments — where delays, failures, and worker safety risks can have significant operational and business consequences — this capability is indispensable. It’s a level of innovation only made possible by this strong partnership,” said Srini Shankar, CEO of Hitachi Digital Services and President and CEO of GlobalLogic.Related LinksHIIM and ServiceNowHMAX by HitachiTrademark NoticeAll trademarks and product names are the property of their respective owners.About Hitachi Digital ServicesHitachi Digital Services, a wholly owned subsidiary of Hitachi, Ltd., is a global systems integrator powering mission critical platforms with people and technology. We help enterprises build, integrate, and run physical and digital systems with tailored solutions in cloud, data, IoT, and ERP modernization, underpinned by advanced AI. By combining Information Technology and Operational Technology (ITxOT), we drive efficiency, innovation, and growth across industries. With over 110 years of Hitachi Group’s engineering and technology leadership, Hitachi Digital Services is powering smarter platforms for a safer, more sustainable future. For more information on Hitachi Digital Services, please visit the company’s website at www.hitachids.com. About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi aims to be a global leader in continuously transforming social infrastructure through digital, contributing to aharmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates worldwide across four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – as well as a Strategic SIB Business Unit focused on new growth areas. With Lumada at its core, Hitachi creates value by combining data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2025 (ended March 31, 2026) totaled 10,586.7 billion yen, with 606 consolidated subsidiaries and approximately 290,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has demonstrated measurable improvement in Power Usage Effectiveness (PUE)(1) at an operational data center, reducing cooling energy consumption while maintaining stable operation. The project was conducted at the Fujitsu AKASHI Data Center operated by Fujitsu Limited, using existing multi—vendor infrastructure (a mix of equipment from multiple manufacturers).While traditional optimization focuses on individual equipment, this demonstration applied holistic control across the entire cooling system, including shared cooling infrastructure(2) and air handling units (AHUs) in server rooms. This system—level approach unlocks new energy savings potential and provides a scalable pathway to improve efficiency in existing data centers.Data center cooling system (Fujitsu AKASHI Data Center)(3)Addressing a Critical Industry ChallengeWith global data center demand surging, energy consumption has become a key constraint. Cooling systems alone account for over 60% of non—IT electricity use(4). Existing facilities prioritize operational stability when controlling cooling systems, making it difficult to incorporate energy optimization as a parallel priority. Further, the increase in AI workloads (the heavy computational processes required to run AI) has made operational requirements more demanding, limiting the effectiveness of existing energy—saving methods, especially those with multi—vendor setups.Demonstration Highlights and ResultsA key differentiator of this project was deployment without service interruption. Leveraging vendor agnostic cooling system optimization technology developed by MHI's Research & Innovation Center, MHI conducted simulations and demonstrated optimized control.Temperature distribution in the server room was identified as a key bottleneck, and rebalancing of airflow by managing air conditioning units improves the temperature distribution by 2℃ in return providing substantial headroom for optimizing other cooling systems. By fine—tuning the operation points of shared cooling infrastructure based on simulations and maintaining cooling water at an appropriate temperature, the project delivered a 2.3% energy reduction across the entire cooling system. In addition, the energy efficiency (COP)(5) of the centrifugal chillers increased by more than 1.2 points.This demonstration project was conducted in just one of the several server rooms in the data center. When the scope is scaled across all the server rooms, cooling system energy savings are projected to reach 7.6%, significantly enhancing overall PUE.Demonstration results and future potential"Operational data centers need to improve energy efficiency while utilizing existing equipment," said Shoji Yamasaki, General Manager, Data Center & Energy Management Department at MHI. "This demonstration proves that system—level cooling optimization—especially in multi—vendor environments—can deliver tangible results under real operating conditions."Going forward, MHI will further expand this approach, integrating decarbonized energy, resilient power systems, high—efficiency cooling, and advanced digital solutions to support sustainable and reliable data center operations worldwide.(1) Power Usage Effectiveness (PUE) is an indicator of how efficiently a data center uses power. The closer to 1.0, the greater the efficiency.(2) Shared Cooling infrastructure comprises equipment for cooling the entire data center, including cooling towers, cooling water pumps, chilled water pumps, and centrifugal chillers.(3) The "header" in the diagram is the main piping system that consolidates and distributes multiple systems of chilled and cooling water, enhancing stable supply and controllability. The "buffer tank" temporarily stores chilled or cooling water, absorbing fluctuations in flow rate and pressure to support stable operation of equipment. A UPS (Uninterruptible Power Supply) ensures a continuous supply of power in case of outages or under abnormal power conditions.(4) Figures from the International Energy Agency (IEA). For details, see the IEA website.https://www.iea.org/data-and-statistics/charts/share-of-electricity-consumption-by-data-centre-and-equipment-type-2024(5) Coefficient of Performance (COP) is an indicator of energy efficiency (effectiveness of cooling or heating relative to the input electricity). Higher the value, greater the energy efficiency.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereinafter, Mitsubishi Motors) and Highlanders, Inc. (hereinafter, Highlanders), a startup originating from the University of Tokyo, today announced that they have signed a Memorandum of Understanding (MOU) to collaborate in establishing a new industrial foundation where humans and robots work together. Under this MOU, the two companies will explore the joint development of humanoid robots for use at Mitsubishi Motors’ manufacturing facilities as well as mass production of Highlanders products at Mitsubishi Motors’ Kyoto Plant.The environment surrounding Japan’s manufacturing industry is undergoing significant change, with labor shortages, increasingly sophisticated manufacturing operations, and the need for more flexible manufacturing systems emerging as major challenges. Mitsubishi Motors is committed to creating new value by collaborating with a diverse range of partners, including startups, to address these future challenges. Highlanders, meanwhile, aims to help solve workforce-related issues through humanoid robots and advanced robotics technologies, with the goal of realizing a society where humans and robots collaborate seamlessly. Through this partnership, the two companies seek to create new value in manufacturing and enhance industrial competitiveness.As a first step in its joint development project with Highlanders, Mitsubishi Motors plans to utilize humanoid robots at its own manufacturing facilities. Through practical use, the company will accumulate operational data and know-how while deepening its expertise in the field of humanoid robotics and evaluating opportunities for future development and production.In parallel, Mitsubishi Motors will leverage its proven expertise in mass-production engineering, quality assurance, durability and safety design, integrated mechatronics control technologies, and factory operations to explore the production of Highlanders’ humanoid robots. The companies will examine the feasibility of commencing production in early 2027 by utilizing currently unused buildings at Mitsubishi Motors’ Kyoto Plant.This marks the first collaboration of its kind between an automotive manufacturer and a humanoid robotics developer involving mass production. By gaining an operational and manufacturing partner, Highlanders expects to accelerate the growth of both companies’ humanoid robotics businesses.Mitsubishi Motors has already invested in Highlanders and plans to make additional investments in the future.Moving forward, the two companies will continue their collaborative efforts toward realizing a society in which humans and robots work together.Comment from Takao Kato, chairman of the board, representative executive officer and CEO of Mitsubishi Motors Corporation"Our collaboration with Highlanders represents a challenge aimed at building a new industrial foundation in which humans and robots work together. At the same time, it provides Mitsubishi Motors with a valuable opportunity to deepen our technological and business expertise in the field of humanoid robotics. By utilizing humanoid robots in our own manufacturing facilities and supporting the production of Highlanders products, we aim to leverage the outcomes of this collaboration to drive our growth and enhance corporate value.”Comment from Hiroya Masuoka, representative director and CEO of Highlanders, Inc."At Highlanders, our mission is to address a wide range of industrial challenges through robotics and physical AI technologies. We believe that achieving mass production of domestically developed humanoid robots through this partnership with Mitsubishi Motors, which brings decades of manufacturing expertise, represents a significant step toward achieving this goal. Furthermore, deploying our robotics technologies within Mitsubishi Motors’ manufacturing operations will provide a valuable opportunity to drive technological advancement in our products. By maximizing the value of this collaboration, we look forward to expanding our mutually beneficial relationship with Mitsubishi Motors.” Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 13, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced that it has developed an Online Medical Certificate Integration Service, which enables online completion of insurance claim procedures for life and medical insurance. This service has been adopted by Aflac Life Insurance Japan Ltd. (Aflac Life Insurance Japan) and The Cancer Institute Hospital of JFCR (Cancer Institute Hospital). The service will commence operations at the end of August 2026.Through this service, which connects patients, medical institutions, and insurance companies, Aflac Life Insurance Japan aims to improve the convenience of insurance claim procedures for policyholders and beneficiaries, while Cancer Institute Hospital seeks to reduce the workload on medical staff involved in creating medical certificates. This initiative is part of Fujitsu's efforts to expand its Personalized Experience offering, which integrates real and digital elements to provide optimal financial services to individuals under "Uvance for Finance".BackgroundInsurance claims for life and medical insurance often require the submission of medical certificates issued by healthcare institutions. The process of creating these certificates contributes to the workload of medical professionals. Furthermore, the exchange of medical certificates has traditionally relied on in-person interactions or postal mail, which can be burdensome for both healthcare institutions and policyholders/beneficiaries. There has been a demand for a simpler and more reliable procedure that ensures security.To address these challenges, Fujitsu developed and is now offering the Online Medical Certificate Integration Service, which allows insurance claim procedures to be completed entirely online. In developing this service, Fujitsu, Aflac Life Insurance Japan, and Cancer Institute Hospital conducted a proof-of-concept from June 30, 2025, to November 30, 2025, to verify the efficiency of the medical certificate creation process, from request to receipt. The experiment confirmed benefits such as a reduction in the time required from requesting to issuing medical certificates.Service overviewThis service enables the entire process, from requesting insurance benefits to receiving medical certificates, to be completed online. Leveraging Fujitsu's expertise in electronic medical record implementation and secure network environments, the service ensures safe and reliable procedures.With this service, when a policyholder applies for insurance benefits online after receiving treatment or hospitalization, the insurance company that accepted the application determines the necessity of a medical certificate based on the application and contract details, and then informs the policyholder/beneficiary. If a medical certificate is required, the policyholder/beneficiary can make a request for the creation of a medical certificate online, a process that previously required visiting the medical institution's reception desk.Healthcare institutions can create medical certificates using the service's medical certificate creation support tool. This tool converts inpatient and outpatient data held by the medical institution into a format aligned with the insurance company's specified medical certificate items. By integrating this data into the medical institution's existing medical certificate creation support system, the tool helps streamline data entry and reduce processing time. Once the medical institution uploads the completed medical certificate to the service, both the policyholder/beneficiary and the insurance company can access it online.Figure 1: Overview of the Online Medical Certificate Integration ServiceAflac Life Insurance Japan and Cancer Institute Hospital anticipate that this service will enhance convenience for policyholders and beneficiaries by eliminating the need for hospital visits and waiting times for insurance claim procedures. Additionally, it will improve the efficiency of medical certificate creation for healthcare institutions and reduce costs and effort associated with paper-based and postal processes.Future PlansFujitsu aims to introduce this service to approximately 20 life insurance companies and 400 medical institutions by fiscal year 2031. Through this initiative, Fujitsu, while leveraging the insights gained from practical operations, will promote the advancement of business processes related to medical certificate collaboration and, by building a reliable system, contribute to creating an environment where medical professionals can focus on their core duties and enhance convenience for patients and other users of medical institutions.Furthermore, Fujitsu will advance towards a society that supports people's lives by providing seamless financial experiences through "Uvance for Finance", which enhances financial operations with data and AI.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 100,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.5 trillion yen (US$23 billion) for the fiscal year ended March 31, 2026 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 9, 2026 - (JCN Newswire via SeaPRwire.com) - JCB Co., Ltd. (JCB), Resona Holdings, Inc. (Resona) and ODAWARA AUTO-MACHINE MFG. Co., Ltd. (ODAWARA) have entered into a memorandum of understanding (MOU) to jointly develop and implement Ultra-Wideband (UWB) wireless payment solutions for public bus services.This initiative builds on the basic agreement signed on March 4, 2026, between JCB and Resona for the commercialization of UWB payments. With ODAWARA — Japan’s leading manufacturer of fare collection equipment for transit operators — joining the alliance, the three companies will accelerate the practical application of this technology in the public transportation sector.UWB is a next-generation wireless communication technology that features high-speed data transmission and highly accurate positioning capabilities. Unlike conventional contactless (NFC) or QR code payments, UWB enables completely hands-free transactions. Passengers can board and alight seamlessly without the need to tap smartphones or scan devices.Background and ObjectivesWhile global expectations for UWB applications in standard ticket gates and retail checkouts are rising, hands-free solutions for open-boarding public transportation — such as buses and streetcars without physical gates — have remained technologically challenging.Concurrently, the Japanese bus industry faces critical challenges, including driver shortages and an aging workforce. Drivers are increasingly burdened by managing diverse payment methods and assisting passengers with fare inquiries, which often causes delays during peak congestion.To address these pressing issues, JCB, Resona, and ODAWARA will launch a joint project in collaboration with active bus operators. Technical and payment verification (including precise boarding/alighting data capture) will commence in FY2026, with small-scale commercial rollouts in FY2027, aiming for full-scale commercial deployment in FY2028.RoadmapFY2026: Launch of technical trials and Proof of Concept (PoC) with bus operatorsFY2027: Initial small-scale commercial implementationFY2028: Full-scale commercial deployment and expansionAnticipated BenefitsFor Passengers (Users):Completely Hands-Free: No need to take out smartphones, wallets, or cards when boarding or exiting.Personalized Mobility Services: Real-time, location-based value delivery via smartphones or in-vehicle displays, including targeted coupons, loyalty points, transit guidance, and congested-route alerts. For Bus Operators:Operational Efficiency: Significant reduction in driver workload by eliminating manual fare handling and onboard payment troubleshooting.Enhanced Safety and Punctuality: Shorter boarding times mitigate delays, allowing drivers to focus entirely on safe driving.Data-Driven Operations: Leveraging high-precision UWB location data to visualize congestion patterns and optimize fleet scheduling.Future OutlookAs part of this strategic collaboration, ODAWARA has officially joined the FiRa® Consortium to actively promote the global standardization of UWB technology in transit payment use cases. Together with consortium partners, JCB, Resona, and ODAWARA will drive technical architecture standardization and user experience (UX) design.Looking beyond public transportation, the three companies intend to collaborate with a diverse range of domestic and international partners to expand the UWB payment ecosystem into smart retail, MaaS (Mobility as a Service), and smart city infrastructure. Corporate Profiles & Media ContactsAbout FiRa ConsortiumThe FiRa Consortium is a member-driven organization dedicated to transforming the way we interact with our environment by enabling precise location awareness for people and devices using the secured fine-ranging and positioning capabilities of Ultra-Wideband (UWB) technology. FiRa does this by driving the development of technical specifications and certification, advocating for effective regulations, and by defining a broad set of use cases for UWB. To learn more about UWB and the FiRa Consortium, visit: www.firaconsortium.org.About ODAWARA AUTO-MACHINE MFG. Co., Ltd.Guided by our corporate motto, “Serving society with a pioneering spirit,” we specialize in fare collection equipment for public transportation, such as local buses. By delivering innovative products, services, and digital transformation (DX) solutions, we aim to improve the sustainability of public transportation and revitalize local communities.For more information, please visit: https://www.odawarakiki.com/ About Resona Holdings, Inc.With the Group's purpose of "Beyond Finance, for a Brighter Future." we continue to take on the challenge of transformation and creation in order to transform the future into a positive one with ideas that go beyond the framework of finance. Adhering to our basic stance of "customer joy is Resona's joy," we will work to "strengthen value creativity" and "next-generation management infrastructure" to respond to customers and local communities.For more information, please visit: https://www.resona-gr.co.jp/holdings/english/About JCB Co., Ltd.JCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 72 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 181 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide.For more information, please visit: www.global.jcb/en/Media ContactsJCB Corporate Communications Anna TakedaTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jpODAWARA AUTO-MACHINE MFG. Co., Ltd. Email: contact_NBPD@odawarakiki.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 6, 2026 - (JCN Newswire via SeaPRwire.com) - JCB Co., Ltd. (Headquarters: Minato-ku, Tokyo; Chairman & Chief Executive Officer: Takayoshi Futae; hereinafter: JCB), Japan’s only international payment brand, and MUFG Bank, Ltd. (President & CEO: Masakazu Osawa), a consolidated subsidiary of Mitsubishi UFJ Financial Group, Inc. (President & Group CEO: Junichi Hanzawa; hereinafter "MUFG"), have entered into a Memorandum of Understanding (MOU) regarding a comprehensive strategic alliance in the ASEAN region.This alliance aims to leverage our complementary strengths by utilizing both companies’ customer bases and financial and payment networks to jointly drive business expansion and create new value across ASEAN.Purpose and Background of the AllianceIn ASEAN, sustained economic growth is driving the expansion of the affluent segment, alongside the growing adoption of digital payments. As a result, demand for financial and payment services is becoming increasingly sophisticated and diverse.In this context, MUFG Bank’s partner bank network, investments in digital businesses, and financial infrastructure will be combined with JCB’s global payment network, Japan’s largest merchant network, and extensive service expertise. By integrating these capabilities with financial services, such as deposits and investments, the two companies aim to create new value, particularly in affluent customer segments and digital payment areas.Key Areas of CollaborationStrengthening Financial Services for Affluent Customers in ASEANLeveraging partnerships with MUFG’s partner banks, we will offer card products that provide exclusive and unique experiences and benefits in Japan for affluent customers in ASEAN. In addition, by linking these card products with financial services, such as deposits and investments, we will deliver enhanced value. As an initial initiative in fiscal year 2026 (ending March 2027), we plan to issue a new premium card in Indonesia, which will be JCB’s highest-tier card ever issued outside Japan.Expansion of Collaboration in the ASEAN Payment DomainBoth companies will explore collaboration between MUFG’s investees in the digital finance sector and JCB’s payment capabilities. Through these efforts, we will consider expanding cross-border payment solutions and mobile services, with the aim of accelerating the development of digital payment ecosystems in ASEAN.By combining their customer bases and payment expertise, the two companies will promote the advancement of financial services and create new business opportunities and synergies.Building Partnerships with Japanese Companies and Promoting Japan as a Tourism-Oriented NationThis alliance aims to establish and expand a “Japan-led financial and payment partnership platform” centered on MUFG Bank and JCB in ASEAN. Building on this foundation, we will broaden partnerships not only with partner banks and digital financial players but also with a wide range of Japanese companies, thereby enhancing the global reach of Japanese brands and services.Beyond financial and payment services, the alliance will drive new business creation through collaboration with Japanese companies and contribute to strengthening Japan’s presence in ASEAN.Through these initiatives, both companies aim to help build a new economic sphere connecting ASEAN and Japan, while supporting efforts to further position Japan as a leading tourism destination.Branding ImageFuture DevelopmentsBased on this MOU, both companies will move forward with concrete initiatives. Leveraging this alliance, we will further expand partnerships with Japanese companies and strive to achieve sustainable growth and create new value in ASEAN.About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 72 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 181 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Contract Signing CeremonyTOKYO, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries, Ltd. (MHI) has signed a contract with Taiwan High Speed Rail Corporation (THSRC), the operator of the Taiwan High Speed Rail (THSR) network, for maintenance tools and equipment for the Yanchao Main Workshop in southern Taiwan. The Yanchao Main Workshop is a facility for maintenance and inspection of trains owned by THSRC. For this project, MHI will deliver, install, and conduct testing and commissioning of maintenance tools and equipment for the Yanchao Main Workshop.THSRC is currently introducing the new N700ST series trains, with commercial operation scheduled to begin in the second half of 2027. This project aims to strengthen the maintenance system in line with the introduction of the new N700ST series trains, contributing to further improvements in the THSR network's transportation services.Since its inauguration in 2007, the THSR network has been widely utilized as core transportation infrastructure in Taiwan. Annual ridership has increased significantly from about 15 million at the time of opening to approximately 82 million in 2025. Currently, the network serves an average of approximately 230,000 passengers per day, and its cumulative ridership has surpassed 1 billion, playing a vital role in supporting economic activity and mobility in Taiwan.The THSR Core System Supply Contract was awarded in 2000 to a consortium of seven Japanese companies, including MHI, and commercial operations commenced in January 2007. Since the inauguration, MHI has contributed to the development of the THSR network through involvement in such projects as the Nangang Extension Project and the Trackwork and Core System for the Zuoying Depot. This project reflects recognition of MHI's longstanding track record and technical expertise.Going forward, MHI will continue to leverage its technology and expertise in transportation systems and project management capabilities to contribute to the further development of the THSR network, and the realization of safe and reliable service.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit: www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

NEW YORK, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi Rail has successfully completed the acquisition of Clever Devices, a leading U.S.-based provider of Intelligent Transportation Systems for transit agencies around the world.Clever Devices is recognized for its pioneering technology solutions that enhance fleet management, passenger experience and operational efficiency for mass transit agencies. The company has offices across the United States, Europe and South America.The acquisition of a company with deep digital expertise and projected 2026 revenues of over $220 million enables Hitachi Rail to reflect the increasing demand for more integrated transportation systems. With completion of the transaction, Hitachi Rail extends its footprint beyond rail into multimodal mobility and further strengthens its presence in North America.With over 600 employees and a customer base that includes 8 of the 10 largest North American transit agencies, Clever Devices has a strong track record of innovation and delivery. Its Intelligent Transport System (ITS) solutions are a critical enabler of increased public transport usage, improving the accuracy of information and boosting service punctuality. These solutions are deployed across public mobility systems, including buses as well as railways. In addition to its strong North American presence, Clever Devices has achieved substantial growth in markets such as Brazil and Chile, as well as in Europe, including Italy.Clever Devices portfolio of onboard and centralised data solutions augments Hitachi's HMAX Mobility suite of physical AI solutions, bringing enhanced functionality and benefits for customers across public transport systems globally.HMAX for Rail sits as part of HMAX Mobility ​ and is Hitachi Rail's digital asset management platform that optimizes railway performance by connecting data from fleets of trains, signalling assets and infrastructure to create an operational twin of rail systems. It combines advanced sensor technology, rail expertise, AI and edge computing to maximize performance, extend asset life and optimize costs.Giuseppe Marino, Group CEO, Hitachi Rail, said:​"This is a key step in advancing our strategy to drive the digital transformation of public transport. We are combining Clever Devices' strong capabilities in intelligent transportation systems with our global reach and HMAX Mobility suite of solutions. With this acquisition, we are broadening our scope beyond rail, strengthening our footprint in North America, and laying the platform to help cities develop more integrated, sustainable and efficient transportation networks."As part of the integration, where he led the launch of Hitachi's Industrial AI portfolio. As CEO, Frank will focus on accelerating growth, strengthening market positioning and driving long-term value creation for the Clever Devices business.Frank Antonysamy, CEO, Clever Devices, a Hitachi Group Company, said:​"Joining Clever Devices at this important moment is a great opportunity. As part of Hitachi Rail, we are well positioned to leverage Hitachi's investments in HMAX and more than 115 years of OT expertise, to accelerate innovation, expand our global reach and deliver enhanced value to transit agencies and passengers through our advanced digital mobility solutions"Hitachi Rail's growing footprint in North America is underlined by recent investments including the $110m opening of its digital factory in Hagerstown, Maryland, and a CA$30m investment in a new Canadian headquarters.Hitachi Rail collaborated with SSIB, Hitachi's Strategic Social Innovation Business Unit, on the acquisition, supporting the One Hitachi initiative and creating further opportunities across the mobility sector. The business will also benefit from the wider digital expertise of Hitachi Group companies, including Hitachi Digital, GlobalLogic and Hitachi Digital Services.About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi aims to be a global leader in continuously transforming social infrastructure through digital , contributing to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates worldwide across four sectors - Digital Systems & Services, Energy, Mobility, and Connective Industries - as well as a Strategic SIB Business Unit focused on new growth areas . With Lumada at its core, Hitachi creates value by combining data, technology and domain knowledge to solve customer and social challenges. Revenues for FY 202 5 (ended March 31, 202 6 ) totaled 10,586 .7 billion yen, with 6 06 consolidated subsidiaries and approximately 2 9 0,000 employees worldwide. Visit us at www.hitachi.com .About Hitachi RailHitachi Rail is committed to driving the transition to sustainable mobility and has a clear focus on partnering with customers to rethink mobility. Its mission is to help every passenger, customer, and community enjoy the benefits of more connected, smooth, and sustainable transportation. With a turnover of more than €7 billion and 24,000 employees in more than 50 countries, Hitachi Rail is a reliable partner for the world's best transport companies. The company's presence is global, but the company is local, with success based on developing local talent and investing in people and communities. Its international expertise and experience covers every part of urban ecosystems, main lines and freight railways, from high - quality production and maintenance of rolling stock to digital signaling, payment systems and smart operations. Hitachi Rail, famous for Japan's iconic high -speed train, leverages the digital and artificial intelligence expertise of Hitachi Group companies to accelerate innovation and develop new technologies. For more information, visit hitachirail.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer’s disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease (AD) and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer’s Association International Conference® 2026 (AAIC®) from July 12-15 in London and online. Eisai will present 52 abstracts across its AD portfolio at AAIC. Highlights include a Developing Topics Session and a Featured Research Session on lecanemab, featuring four and six oral presentations, respectively, alongside 10 additional key oral presentations and 32 posters. Eisai will also host a symposium on early intervention in AD.​Key PresentationsA Developing Topics Session will feature emerging clinical evidence and practical use considerations for the subcutaneous formulation of lecanemab, including clinical trial and real-world patient experience. A Featured Research Session will highlight data from the LEADER study evaluating real-world lecanemab use in diverse US clinical settings three years post-approval, including results on maintenance dosing with IV treatment every four weeks and the first reported findings of at-home subcutaneous administration.Presentations on the Phase 3 AHEAD 3-45 study in preclinical AD will highlight progress of the trial including updates on participant retention and engagement.Additional oral presentations will highlight a Phase 2 trial of etalanetug with background lecanemab, and the effect on tau pathology.“We are sharing a broad and robust data set at AAIC spanning the Alzheimer’s disease continuum, multiple therapeutic targets, and modes of administration, underscoring our commitment to advancing care for this complex disease,” said Lynn D. Kramer, M.D., FAAN, Chief Clinical Officer, Deep Human Biology Learning (DHBL), Eisai. “Growing real-world experience with lecanemab, along with insights from patients, care partners, and clinicians, continues to add to our understanding of the value of early intervention, long-term treatment, and patient choice in care delivery.”AAIC 2026 Presentations Relating to Eisai's Key Compounds and ResearchDeveloping Topics Session #1-32-FRS-C: Lecanemab Subcutaneous Formulation in Early Alzheimer's Disease: Emerging Clinical Evidence and Practical Use Considerations4:15-5:45 PM BST, Sunday, July 12Session ProgramOverview of Lecanemab Subcutaneous Formulation in Early Alzheimer’s DiseaseSafety Profile of a Subcutaneous Lecanemab FormulationClinical Outcomes and Patient Experience of Subcutaneous Lecanemab Administration from an Alzheimer's Disease Treatment CenterReal-World Patient-Reported Outcomes with Subcutaneous Lecanemab Treatment in Early Alzheimer's Disease in the United States: A Case SeriesFeatured Research Session #4-33-FRS-A: Lecanemab Three Years Post-Approval: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) in Diverse US Clinical Settings4:15-5:45 PM BST, Tuesday, July 14Session ProgramA Three-year Update of Lecanemab in Early Alzheimer’s Disease: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER)Lecanemab Use and Clinical Outcomes by APOE ε4 Status, Concomitant Medications, Sex, Race, and Ethnicity: Findings from the LEADER StudyReal-World Use of Lecanemab Once-Monthly Maintenance Dosing in Early Alzheimer’s Disease: A Multicenter, Retrospective US StudyThe First Reported Findings of At-Home Subcutaneous Lecanemab Administration: A Real-World, Multicenter, Retrospective StudyReal-World Insights on Lecanemab Maintenance Therapy Patient Pathway From A Multicenter, Real-World, Retrospective Study (LEADER)Physician and Perceived Patient Satisfaction with Lecanemab Maintenance Therapy: An Update from the LEADER StudyAdditional Oral Presentations Asset / Topic, Presentation Date and Time (BST)Presentation TitleLecanemabJuly 12 (Sun.)2:00 – 3:30 PMDeveloping Topics Session 1-23-FRS-B: Developing Topics in Amyloid Targeting Therapies: Global Perspectives from Trials to Real World EvidencePresentation: Treatment Actions following ARIA in Patients Treated with Lecanemab: Evidence from a Post-Marketing Observational Study in Japan (Abstract ID TBA)LecanemabJuly 13 (Mon.)8:00 – 8:45 AMDeveloping Topic Session #2-6-DEV: Developing Topics in Amyloid Targeting Therapies and Real-World OutcomesPresentation: Sex-Based Outcomes of Lecanemab in Early Alzheimer’s Disease: A Comprehensive Multicenter, Real-World, Retrospective Study (LEADER) (Abstract ID TBA)LecanemabJuly 13 (Mon.)9:00 – 10:30 AMFeatured Research Session #2-15-FRS-A: External Controls In Alzheimer’s Clinical Trials: How Far Away Are We?Presentation: External Controls in Open-Label Extensions: Insights from Clarity AD (Abstract ID 982)LecanemabJuly 14 (Tues.)8:00 – 8:45 AMDeveloping Topics Session #3-4-DEV: Developing Topics in Pathological Changes Resulting from Amyloid Targeting Treatment in Alzheimer's DiseasePresentation: Broad Modulation of Core Tau Biomarkers, Including pTau205 Following Lecanemab Treatment (Abstract ID 13515)LecanemabJuly 14 (Tues.)8:00 – 8:45 AMDeveloping Topics Session #3-4-DEV: Developing Topics in Pathological Changes Resulting from Amyloid Targeting Treatment in Alzheimer's DiseasePresentation: Tau PET Change in CLARITY-AD (Abstract ID 13333)LecanemabJuly 14 (Tues.)8:00 – 8:45 AMDeveloping Topics Session #3-3-DEV: Developing Topics in Factors Affecting Fluid BiomarkersPresentation: Racial And Ethnic Differences in %p-tau217 Associations with Cognitive Performance and Amyloid PET In Preclinical AD (Abstract ID 13712)LecanemabJuly 14 (Tues.)9:00 – 10:30 AMFeatured Research Session #3-15-FRS-A: Anti-Amyloid Therapy: Real World ExperiencePresentation: Lecanemab Clinical Practice: A Multicenter, Surveillance Safety Study from the ALZ-NET Registry (Abstract ID 6202)Etalanetug (E2814)July 13 (Mon.)9:00 – 10:30 AMFeatured Research Session #2-17-FRS-A: Alzheimer's Therapy: Mechanisms Beyond AmyloidPresentation: Baseline Imaging Characteristics of Participants in a Phase 2 Trial of Etalanetug and Concurrent Lecanemab (Abstract ID 10449)Etalanetug (E2814)July 13 (Mon.)9:00 – 10:30 AMFeatured Research Session #2-17-FRS-A: Alzheimer's Therapy: Mechanisms Beyond AmyloidPresentation: Etalanetug and Tau Tangle Specific Plasma eMTBR-tau243 in DIAD (Abstract ID 9850)BiomarkersJuly 14 (Tues.)8:00 – 8:45 AMDeveloping Topics Session #3-3-DEV: Developing Topics in Factors Affecting Fluid BiomarkersPresentation: Refining Plasma pTau217/Aβ42 Cutoffs for Amyloid Positivity in an Asian Cohort with High Cerebrovascular Disease Burden (Abstract ID TBA)Poster PresentationsAsset / Topic, Presentation Date**Title, Abstract NumberLecanemabJuly 12 (Sun.)Characterization and Utilization Assessment of a Centrally Supported Ride-Share Service Implemented in a Multisite Preclinical Alzheimer’s Clinical Trial (Abstract ID TBA)LecanemabJuly 12 (Sun.)Long-Term Persistence and Patient Characteristics for Intravenous and Subcutaneous Lecanemab in Real-World Use in the United States (Abstract ID 7344)LecanemabJuly 12 (Sun.)Retrospective Case Series of Real-world Clinical and Patient-reported Outcomes with Lecanemab (Abstract ID 9480)LecanemabJuly 12 (Sun.)Retrospective Observational Cohort Study of Real-world Clinical and Patient-reported Outcomes with Lecanemab (Abstract ID 9882)LecanemabJuly 13 (Mon.)Subcutaneous Lecanemab Administration in an Alzheimer’s Disease Treatment Center: Real-World Clinical Outcomes and Patient Experiences (Abstract ID 1556)LecanemabJuly 13 (Mon.)INITIATE-SC: A Multicenter Real-World Study of Subcutaneous Lecanemab Initiation in Early Alzheimer’s Disease (Abstract ID 13568)LecanemabJuly 13 (Mon.)Continued or Time-limited Treatment Benefits of Anti-amyloid Monoclonal Antibodies In Early Alzheimer’s Disease (Abstract ID 13738)LecanemabJuly 13 (Mon.)Early Alzheimer’s Disease Treated with Lecanemab: A Real-World, Retrospective Analysis from a Colorado Neurological Clinic (Abstract ID 12904)LecanemabJuly 13 (Mon.)Communicating Participant Milestones to Enhance Trial Engagement and Retention in a Preclinical Alzheimer’s Trial (Abstract ID 9159)LecanemabJuly 13 (Mon.)Initial Real-World Experience in Using Lecanemab in Hong Kong: Safety and Preliminary PET CT Data (Abstract ID 11962)LecanemabJuly 14 (Tues.)Real-World Lecanemab Treatment in Early Alzheimer’s Disease: A Retrospective Dementia Clinic Case Series Review from a Geriatric Medicine Clinical Practice (Abstract ID 1947)LecanemabJuly 15 (Weds.)A Time and Motion and Patient Satisfaction Study of Subcutaneous Injection of Lecanemab for Patients with Early Alzheimer’s Disease (Abstract ID 13637)LecanemabJuly 15 (Weds.)Differential Costs Of Amyloid-related Imaging Abnormality Management Between Anti-amyloid Treatments: Estimates Based On A Delphi Panel (Abstract ID 9345)LecanemabJuly 15 (Weds.)VISION AD-JP: A Prospective Multicenter Real-world Study of Japanese Patients with Early Alzheimer’s Disease Treated with Lecanemab (Abstract ID 13235)LecanemabJuly 15 (Weds.)Real-World Outcomes with Lecanemab Treatment in a New England Alzheimer’s Disease Center (Abstract ID 1949)LecanemabJuly 15 (Weds.)Estimating the Economic Impact of Delayed Alzheimer's Disease Progression with Lecanemab (Abstract ID 9889)LecanemabJuly 15 (Weds.)Economic, Health, and Quality-of-Life Burden on Caregivers and Study Partners of Lecanemab-Treated Individuals with Alzheimer’s Disease (Abstract ID 6169)Etalanetug (E2814)July 13 (Mon.)A Surrogate Antibody Of Etalanetug, H25L15-hIgG1, and Uptake Of Tau Monomer And Aggregate In Human Macrophages Through Fcγ Receptors (Abstract ID 11847)Etalanetug (E2814)July 14 (Tues.)A Novel CSF eMTBR-tau243 Immunoassay for Detecting AD Tau Pathology and Assessing Etalanetug Pharmacodynamics in DIAD (Abstract ID 6867)BiomarkersJuly 12 (Sun.)Blood-Based Biomarkers in Early Alzheimer’s Disease: Real-World Adoption Trends and Diagnostic Pathways (Abstract ID 13215)BiomarkersJuly 12 (Sun.)From First Visit to Disclosure: Confirmatory Blood-Based Biomarkers and Diagnostic Timing in Alzheimer’s Disease (Abstract ID 13219)BiomarkersJuly 12 (Sun.)Practical Factors Influencing the Use of Confirmatory Blood-Based Biomarkers in Alzheimer’s Care (Abstract ID 132220)BiomarkersJuly 12 (Sun.)Frontline Perspectives on the Real-World Use of Blood-Based Biomarkers in Alzheimer’s Disease (Abstract ID 13480)BiomarkersJuly 13 (Mon.)Evolution of Real-World Blood-Based Biomarker Use in the Lecanemab Patient Pathway: Three-Year Update From the LEADER Study (Abstract ID 13216)BiomarkersJuly 13 (Mon.)Retrospective Analysis of Costs of Amyloid Diagnostic Tests for Alzheimer’s Disease from a Health-system Perspective (Abstract ID 6663)BiomarkersJuly 13 (Mon.)Piloting Digital Cognitive Assessments and a Blood-Based Biomarker to Improve Alzheimer’s Disease Diagnosis (Abstract ID 3554)BiomarkersJuly 13 (Mon.)Real-World Diagnostic Pathways For Alzheimer’s Disease In U.S. Clinical Practice Using Claims And Integrated EHR Data (Abstract 13436)BiomarkersJuly 15 (Weds.)Integrated Peptide-Level Global Proteomics and Co-expression Network Analysis: Insights into Amyloid-beta-Driven Dementia (Abstract ID 10170)Biomarkers (non-clinical)July 12 (Sun.)Proteomic Assessment of CSF Biomarkers of Neurodegeneration from a Minimally Invasive and Serial CSF Collection Technique in Mice (Abstract ID 2306)General ADJuly 13 (Mon.)Could Driving Time to Infusion Sites be an Obstacle to Receiving Alzheimer’s Treatments? (Abstract ID 2151)General ADJuly 13 (Mon.)Treatment Goals for Anti-Amyloid Therapy (AAT) in Early-AD: A Consensus from U.S. Dementia Specialists (Abstract ID 13578)General ADJuly 14 (Tues.)From Feasibility to Real-World Readiness: Interpreting Evidence for Self-Administered Digital Cognitive Assessments (Abstract ID 10780)**Poster viewing time is set from 7:30 AM – 4:15 PM BST on the date of presentationEisai-Sponsored Symposium***Symposium is intended for HCPs onlyAsset / Presentation Date and Time (BST)TitleLecanemabJuly 14 (Tues.)12:30 – 1:45 PMEarly Intervention in Alzheimer’s Disease: Building the Evidence from Pathology to PracticeEisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.MEDIA CONTACTSPublic Relations DepartmentEisai Co., Ltd.TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.(Europe, Australia, New Zealand and Russia)EMEA Communications Department+44 (0) 7739-600-678EMEA-comms@eisai.netEisai Inc. (U.S.)Julie Edelman+1-862-213-5915Julie Edelman@eisai.comAbout lecanemab (generic name, brand name: LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026 and granted Priority Review. The sBLA has been assigned an extended Prescription Drug User Fee Act (PDUFA) action date of August 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.About ProtofibrilsProtofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of soluble Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2About etalanetug (E2814)Etalanetug is an anti-MTBR (microtubule-binding region) tau antibody discovered through collaborative research between Eisai and University College London. It is designed to inhibit the propagation of tau seeds within the brain. Etalanetug is being developed as a potential disease-modifying therapy for tauopathies, including sporadic Alzheimer's disease (AD).Currently, etalanetug is being evaluated in two ongoing clinical studies: the Tau NexGen Phase 2/3 trial in dominantly inherited Alzheimer's disease (DIAD), conducted under the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) and led by Washington University School of Medicine in St. Louis, added to the standard-of-care anti-Aβ protofibril antibody lecanemab (brand name: LEQEMBI), and the Phase 2 Study 202, a global randomized trial in individuals with early sporadic AD, also assessing etalanetug added to lecanemab. In September 2025, etalanetug received Fast Track designation from the U.S. Food and Drug Administration (FDA).About the Collaboration between Eisai and Biogen for ADEisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.About the Collaboration between Eisai and BioArctic for ADSince 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - University College London (UCL) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) have signed a new agreement to extend their long-standing collaboration in drug discovery and development for five more years, taking the partnership through to 2030. This alliance reinforces a unique model built on trust, combining academic excellence with industry expertise to accelerate innovation in neuroscience drug discovery, investigating new ways of treating neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Amyotrophic Lateral Sclerosis and other related disorders.Eisai, a Tokyo-headquartered pharmaceutical company, is globally recognised for pioneering treatments for dementia and other neurodegenerative conditions. One of the most notable outcomes of the UCL–Eisai collaboration to date is the anti-MTBR tau antibody E2814, which was first discovered as part of collaborative research between the two organisations. The antibody is currently being evaluated in the DIAN-TU Phase II/III Clinical trial for Dominantly Inherited Alzheimer’s Disease (DIAD), as well as the Phase II clinical trial for sporadic early AD (Study 202).In total, eight drug discovery projects focusing on a variety of therapeutic targets have been supported through a £10 million investment to date, with further investment committed over the next five years as part of the extension. These efforts are underpinned by a strong commitment to knowledge exchange, reflected in more than 30 scientific outputs including publications and presentations to date, ensuring jointly acquired insights are shared with the wider community, and helping to move the field closer to delivering meaningful outcomes for patients.The renewed agreement launches with collaborative projects targeting novel therapeutic pathways while opening the door to UCL researchers across disciplines to bring forward innovative ideas for co-development.Over the next five years, the alliance will focus on:Moving promising collaborative projects through recognised stage gates of the drug development pathwayActively seeking and advancing high-potential drug discovery projects to tackle neurodegenerationStrengthening the neurodegeneration research talent pipeline by creating specialist scientist roles across joint projectsEnabling researchers to publish and present findings to the wider scientific community, including at international conferencesSustaining close engagement at every level, from senior leadership to project scientists, across both organisations.First launched in 2012 and spearheaded by the UCL Translational Research Office (TRO) and the Faculty of Brain Sciences, the Eisai–UCL alliance exemplifies a bespoke partnership model that goes beyond traditional academia-industry collaborations. Over the past decade, it has created a dynamic ecosystem that accelerates translational research towards the clinic, nurtures early-stage projects, connects scientific pain points with the right expertise and invests in talent development through initiatives such as jointly funded PhDs and long‑term knowledge sharing between the organisations.Professor Geraint Rees, UCL’s Vice-Provost (Research, Innovation & Global Engagement), said: “Long‑term academic–industry partnerships of this depth are rare. The UCL–Eisai alliance shows what can be achieved addressing global health challenges when there is sustained alignment and trust. This five‑year extension gives us the stability to deepen the science, accelerate translation from lab to market, and develop the next generation of research leaders.”Professor Tom Warner, Professor of Clinical Neurology, UCL Queen Square Institute of Neurology, co-chair of the UCL-Eisai Joint Steering Committee, said: “This renewal reflects the maturity of the collaboration and our shared ambition to take on challenging scientific questions in neurodegenerative disease. The next phase enables us to progress promising research discoveries into therapies with a clear pathway towards patients.”Dr Katsutoshi Ido, Eisai’s Chief Scientific Officer and co-chair of the Joint Steering Committee, said: “What distinguishes the collaboration with UCL is the depth of neuroscience expertise and the ability to connect early discovery with patient benefit. The Translational Research Office plays an essential role in supporting the partnership, and by working closely together we can more effectively advance promising research towards new treatments for patients.”Eisai has also announced this month a strategic investment at its manufacturing site in Hatfield, Hertfordshire, United Kingdom, supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions. It demonstrates Eisai’s long-term commitment to strengthening its relationship with the United Kingdom.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL：+81 (0)3-3817-5120University College LondonKristy Tsangkristy.tsang@ucl.ac.ukAbout University College London (UCL)UCL is a global top 10 university, set up in London 200 years ago to offer education for all. Today, we gather 60,000 staff and students, from over 150 countries, to create a unique city within a city – a research and innovation powerhouse that leads the world in subjects spanning the arts, sciences, technology and the humanities. We’ve nurtured 33 Nobel Prize winners, because here, brave ideas have the scale and the support they need to succeed. We are University College London. And here, it can happen. UCL turns 200 in 2026. Join us for a year of bicentennial events and celebration. www.ucl.ac.uk About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit http://www.eisai.eu/ and Eisai EMEA LinkedIn. Eisai actively promotes open innovation with external partners, including academia, biotechnology companies, startups, and pharmaceutical companies worldwide. For partnership opportunities, technology proposals, or research collaborations, please visit: Global Open Innovation and for EMEA External Innovation, contact: externalinnovation@eisai.net Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701), a leading global IT and network transformation services provider, today announced a collaboration with Messer Gases to support the company's digital transformation as part of its Industry 4.0 strategy. With the deployment of Cisco connectivity and security solutions engineered by NEC, Messer Gases is strengthening its digital foundation to accelerate Industry 4.0 initiatives, enabling smarter, more automated, and data-driven operations across its plants.Messer Gases, a Germany-based company with global business in industrial, medical, and specialty gases, has been accelerating its digital transformation initiatives by modernizing processes and expanding the use of technologies to automate operations and improve the efficiency of its plants. Through consulting and integration services delivered over the past three years, NEC has helped modernize Messer's network infrastructure, expand Wi-Fi coverage, and strengthen the security of the industrial network, reinforcing the digital foundation that supports more efficient and automated operations across its facilities.As part of projects contracted with NEC, Messer has invested in modernizing the wireless network infrastructure at its Jundiaí site in São Paulo state, the company's largest operation in Brazil, through the implementation of network technologies that are part of the Cisco unified wired and wireless portfolio. To support the renewal of technology at the site, NEC deployed access points, including Cisco devices and switches to support the company's network.The use of Cisco solutions with cloud-based management has brought greater visibility and operational simplicity to Messer's IT team, enabling them to identify the optimal positioning of antennas and monitor network performance in real time.The infrastructure modernization has been essential to support new digital applications, such as Balcão, which allows gas cylinders to be tracked from production to delivery, eliminating the use of manual records that are more prone to errors or misplacement. The operation has gained efficiency and reliability with the expansion and strengthening of network connectivity.As part of the solution package, NEC also conducted a site survey, providing a technical and strategic mapping of the Wi-Fi network by measuring coverage, signal strength, and interference. The assessment was essential to identifying the best locations for installing access points and ensuring the overall effectiveness of the project.Another important milestone was an upgrade to the Cisco Identity Services Engine (ISE), a network access control platform already included in Messer Gases' short-term roadmap. The solution enables authentication, authorization, and monitoring of devices and users, reinforcing the adoption of the Zero Trust security concept and expanding protection across both wired and wireless networks. The update also improved visitor network access, making it simpler and more controlled.Even before NEC joined as systems integrator, Messer had begun expanding Wi-Fi coverage in 2019, when configurations were still performed manually. The adoption of Cisco unified wired and wireless technologies and its integration with ISE represents a significant technological leap, enabling more automated and intelligent network infrastructure management, a critical step to support the increasing demands of digital transformation."With the advancement of process digitalization and the growing use of applications, connectivity has become a critical factor for our operations. Ensuring stable and high-quality Wi-Fi access is no longer just a matter of convenience, it is essential for productivity and business continuity," said Sandra Deoti, Head of IT at Messer Gases."NEC provided a consulting service that helped us identify which equipment best fit our needs. This work was almost like a mentorship. The partnership with NEC was fundamental to accelerating the implementation in a structured way and with specialized technical support. In addition, NEC repeated the site survey after hearing our feedback, which left us very impressed, the result was excellent and, most importantly, we saw that the customer's voice was truly heard," said Lucas Ferrão, Infrastructure Specialist at Messer Gases."Our partnership with Messer Gases represents an excellent example of what we strive to deliver to our customers every day, providing not only cutting-edge technology but also the expertise of a team shaped by decades of integration experience. Our solutions are also supported by strategic alliances with leading technology providers, enabling us to design highly secure, high-performance networks," said Roberto Murakami, Vice President of Network and Telecom Business Units at NEC Latin America.About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group's approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit www.nec.com, and follow NEC on LinkedIn and YouTube. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, July 2, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced that the Fujitsu Group has received a gold medal in the sustainability rating conducted by EcoVadis, an international rating agency. This marks the first time the Fujitsu Group has achieved a gold medal, ranking it among the top 5% of companies assessed, in recognition of its continuous improvement in sustainability initiatives.About EcoVadisEcoVadis is one of the world's largest sustainability rating platforms, with over 150,000 companies participating from more than 180 countries. As global interest in corporate sustainability activities grows, EcoVadis is widely utilized by many companies as an international benchmark for demonstrating the effectiveness of their sustainability efforts. The EcoVadis sustainability rating comprehensively evaluates companies' activities across four themes based on its unique criteria: "Environment," "Labor & Human Rights," "Ethics," and "Sustainable Procurement."About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 100,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.5 trillion yen (US$23 billion) for the fiscal year ended March 31, 2026 and remains the top digital services company in Japan by market share. Find out more: global.fujitsu Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO // TAIPEI, July 1, 2026 - (JCN Newswire via SeaPRwire.com) - JCB International Co., Ltd., the international operations subsidiary of JCB Co., Ltd., Japan’s only international payment brand, and JCB International (Taiwan) Co., Ltd., announced the launch of JCB contactless payment acceptance on the Taipei Metro.The Taipei Metro, which commenced operations in 1996, is a major urban mass transit system connecting Taipei City and New Taipei City. The network consists of multiple lines with a total length of over 100 kilometers and numerous stations serving key areas. It is widely used for daily commuting as well as by tourists. Along its routes are many of Taiwan’s iconic attractions, including Taipei 101, the National Palace Museum, Ximending, and the Shilin Night Market, making it an essential transportation option for both residents and visitors.With the introduction of JCB contactless payment on the Taipei Metro, JCB Cardmembers can simply tap their contactless JCB Cards or compatible devices at ticket gates to ride. This eliminates the need to purchase tickets or reload transit cards, providing a smoother and more seamless travel experience.In Taiwan, JCB contactless payments are already available not only on the Taipei Metro (including the Circular Line of New Taipei Metro) but also on the Kaohsiung Metro, Taoyuan Metro, and Taichung Metro.JCB contactless payments are increasingly being adopted across public transportation systems worldwide, contributing to improved convenience for both daily travel and tourism. JCB will continue to promote cashless solutions in the transportation sector and strive to expand usage scenarios while enhancing customer convenience.About JCBJCB is a major global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 72 million merchants around the world. JCB Cards are now issued mainly in Asian countries and territories, with more than 181 million cardmembers. As part of its international growth strategy, JCB has formed alliances with hundreds of leading banks and financial institutions globally to increase its merchant coverage and cardmember base. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/ContactAnna TakedaCorporate CommunicationsTel: +81-3-5778-8353Email: jcb-pr@info.jcb.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, June 30, 2026 - (JCN Newswire via SeaPRwire.com) - Hitachi High-Tech Corporation ("Hitachi High-Tech") will establish Innovation Center Eindhoven ("the Center") at High Tech Campus Eindhoven*1 (The Netherlands, "the High Tech Campus") in July 2026. The High Tech Campus is a hub for advanced semiconductor - related technologies, and is one of the largest open innovation centers in Europe, where more than 12,500 employees and over 300 companies gather to develop technologies and products. The Center will conduct work on technology development through open innovation with local academia and deep tech companies*2. Open innovation on the High Tech Campus offers a one - stop environment for everything from principle validation to value validation for developing technologies, enabling new technologies to be brought to market and accelerating their time to market. This will create innovative digitalized assets that combine new technologies tailored to customer needs with advanced AI, including physical AI, and enable innovation on a global scale with a focus on the semiconductor field through HMAX Industry.*1 https://hightechcampus.com/*2 Deep tech companies: Companies that conduct business through scientific discoveries and innovative technologies that solve social issues and have a significant impact on people's lives and societyBack groundCurrently, data traffic volume is increasing due to the rapid spread of AI, and intense capital investment is being made into data centers and base stations. Furthermore, the semiconductor market is expected to develop and grow in future in line with increasing demand for semiconductor devices for automotive applications, such as in electric vehicles and autonomous driving, amid continued implementation of physical AI that functions in the real world. As the market continues to grow, continuous technological innovation is essential, and as semiconductors become smaller, more layered, and more complex, solutions need to be found to complex challenges in order to respond to these technological innovations.History and Overview of Establishing the CenterHitachi High - Tech is advancing research and development by strengthening collaboration with external partners such as academia and industry in order to solve these increasingly complex technical challenges for semiconductor manufacturers. As part of that, research on electron beam technology, which is a core technology of Hitachi High - Tech, has been conducted at Delft University of Technology*3, the Netherlands Organisation for Applied Scientific Research*4, and other partners. While conducting various studies on the implementation of research results into products, Hitachi High - Tech decided to establish the Center in order to quickly provide value to customers by accelerating Lab to Fab*5 in the product development and production processes of Hitachi High - Tech. The High Tech Campus's rich knowledge of electron beams and semiconductors and culture of open innovation will enable rapid and innovative development, reduced time to market and faster launching of mass production. The Center will be operated mainly by Hitachi High - Tech Europe GmbH, and will actively promote various developments, not just the technologies currently under development, while also recruiting local staff. In addition, it will expand collaboration with academia and deep tech companies in various European regions, mainly in the Netherlands.*3 https://www.tudelft.nl/en/*4 https://www.tno.nl/en/*5 Lab to Fab: A business model that provides integrated support from R&D to mass production, creating value such as reducing time from development to market launch (Time to Market).Hitachi High - Tech belongs to the Industrial Solutions Business Unit in Hitachi's Connected Industries (CI) sector, and is focusing on HMAX Industry, a next - generation solutions group that combines domain knowledge and advanced AI with data from a rich installed base of products(digitalized assets). Hitachi High - Tech aims to become a leading company in physical AI, and through its core focus of providing industrial solutions centered on these technologies, aims to maximize lifetime value for our customers and transform industries globally to achieve a prosperous society.The representative comment is as follows.Otto van den Boogaard , CEO of High Tech Campus EindhovenWe are honored to welcome Hitachi High-Tech Europe GmbH to High Tech Campus Eindhoven. Their presence creates new opportunities for collaboration with leading research institutes and industry partners in the semiconductor value chain.Osamu Komuro , Senior Vice President and Executive Officer, and General Manager, Nano -Technology Solution Business Group of Hitachi High-TechThe opening of the Innovation Center Eindhoven is an important step toward accelerating technological innovation and further enhancing customer value. At High Tech Campus Eindhoven, one of Europe’s leading open innovation hubs, Hitachi High-Tech will accelerate the creation of digitalized assets that combine enhancement of its core technologies with advanced AI through collaboration with academia and deep tech companies.Kazuyoshi Matsukaze, Executive Officer of Hitachi High-Tech , and President, Hitachi High-Tech Europe GmbHHitachi High-Tech Europe GmbH have continuously strengthened our development capabilities in Europe through strategic investments, particularly in Germany and Belgium. With the establishment of a new hub in Eindhoven, a region that attracts diverse global talent, we are delighted that this will further enhance our ability to develop and propose innovative solutions and foster an environment for mutual growth and development with our customers.About Hitachi High-Tech’s Semiconductor Manufacturing Equipmenthttps://www.hitachi-hightech.com/global/en/products/semiconductor-manufacturing/ About Hitachi High-Tech Europe GmbHhttps://www.hitachi-hightech.com/eu/en/ Trademark NoticeAll trademarks and product names are the property of their respective owners.About Hitachi High-TechHitachi High-Tech provides cutting-edge technologies, products and services to society and customers with its corporate vision of "Changing the World and Future with the Power of Knowledge" to contribute to a sustainable global environment, healthy, safe and secure lives, and the sustained development of science and industry. We manufacture and sell clinical analyzers, biotechnology products and radiation therapy systems in the healthcare field, semiconductor manufacturing and inspection equipment in the semiconductor field, as well as analytical systems and electron microscopes used in environmental fields and materials research. We are also engaged in a wide range of business areas globally, providing high value added solutions in battery, communication in frastructure, railway inspection, digital and other industrial and social infrastructure fields. We provide solutions through a deeper understanding of the issues facing society and our customers to contribute to realizing a sustainable society. The company's consolidated revenues for FY2025 were approx. JPY 821.7 billion. For further information, visit https://www.hitachi-hightech.com/global/en/ Business ContactCorporate Strategy Office,Hitachi High-Tech Europe GmbHEmail: HTE-CSOffice@hitachi-hightech.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan, June 30, 2026 - (JCN Newswire via SeaPRwire.com) - Honda will commemorate the 40th anniversary of its first FIA*1 Formula One World Championship™ Constructors’ title*2 in 1986 with a series of special programs and events around the world.The first championship title in Honda’s F1™ history was a major milestone that symbolized its spirit of challenge. To commemorate the 40th anniversary of this achievement, Honda will look back on the history of its challenges and victories in F1™ while conducting a global showrun program featuring the Williams Honda FW11*3 (FW11) to celebrate with motorsports fans around the world.At the Goodwood Festival of Speed 2026, to be held in West Sussex, United Kingdom (July 9–12 local time), the FW11 will be driven by Damon Hill and Ryo Michigami. Damon Hill is one of the legendary drivers who won the F1™ Drivers’ Championship in 1996, while Ryo Michigami won the 2000 All Japan GT Championship (JGTC) title with the NSX and has competed in top categories in Japan and overseas for many years. In addition, the Prelude HRC Concept, first unveiled at Tokyo Auto Salon in January, is also scheduled to take part in showruns. It will be driven by Jessica Hawkins, Head of F1 Academy*4 and Driver Ambassador at Aston Martin Aramco Formula One™ Team.*1 FIA : Fédération Internationale de l’Automobile*2 Annual title awarded to the team that scores the most points over the course of a season.*3 The F1™ car that Honda entered in 1986 by supplying engines to what is now Atlassian Williams F1™ Team.*4 An all-female racing series organized by F1™, established to support the development of young female drivers.Honda key activities to commemorate the 40th anniversary of Honda’s first F1™ titleThe FW11, renowned for its dominant performance and powered by a 1.5-liter V6 twin-turbo engine, will appear at major motorsports events around the world.Event schedule (planned)April 19: Shin Motor Fan Festa (Shizuoka, Japan) As the first event in the program, the FW11 completed demonstration runs at Fuji Speedway. Footage of the demonstration is available on Honda’s official YouTube channel. https://youtu.be/-UTXXYm-znAJuly 9-12: Goodwood Festival of Speed 2026 (West Sussex, United Kingdom)August: Rolex Monterey Motorsports Reunion (California, United States)Honda’s first F1™ titleIn 1986, the FW11 demonstrated outstanding competitiveness throughout the season, winning nine of the 16 Grands Prix and delivering Honda’s first Constructors’ Championship title. The achievement marked the beginning of a golden era for Honda in F1™, during which the company would go on to secure multiple championship victories.Further information regarding Honda’s activities at the Goodwood Festival of Speed 2026 and the history of Honda in F1™ will be made available on the following websites:- Honda First F1™ Title 40th Anniversary (Williams)https://global.honda/en/F1/williams/- Goodwood Festival of Speed 2026https://global.honda/en/goodwood/2026/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan, June 30, 2026 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. today issued the Honda ESG Report 2026, posting it on the company website.As one of the tools to enhance communication with a diverse range of stakeholders, Honda has been issuing its annual "Honda ESG Report," which comprehensively summarizes the company’s approach and initiatives to enhance its sustainability from the Environment, Social, and Governance (ESG) perspectives.Honda has realigned the powertrain portfolios and product launch plans for its motorcycle, automobile, and power products businesses, considering changes in the current business environment and demand trends. Additionally, Honda has reset the management indicators and targets toward achieving the company goal of carbon neutrality by 2050. Moreover, Honda has reassessed its corporate governance structure to ensure the steady execution of each business strategy and enable bold and transparent decision-making.This year’s Honda ESG Report outlines the rationale behind these new environmental indicators and targets, the roadmap for achieving the new targets, and initiatives to enhance Honda corporate governance.English language version: https://global.honda/en/sustainability/report.htmlCover of the Honda ESG Report 2026Honda is striving to evolve as a company to continue creating new value based on the company’s unchanging desire since its founding to “help people and society” and “help people expand their own life’s potential.” To this end, Honda is committed to communicating the approach and initiatives Honda is taking to ensure its sustainability by providing easy-to-understand information through the Honda ESG Report. Moreover, by increasing opportunities to engage in dialogue with its stakeholders, Honda will continue to advance its sustainability initiatives and strive to achieve a steady increase in corporate value, which will enable Honda to continue to be a company society wants to exist into the future.Main contents of the Honda ESG Report 2026:- Overview of Honda sustainability initiatives (basic approach, sustainability management structure, etc.)- Environmental initiatives (climate change, pollution, water, etc.)- Social initiatives (human rights, human resources, safety, etc.)- Governance initiatives (corporate governance, compliance, risk management, etc.) Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Osaka, Japan, June 30, 2026 - (JCN Newswire via SeaPRwire.com) - Sharp Corporation signed a Memorandum of Understanding (MOU) with major global satellite operator and space solutions provider SES (*1) to collaborate on satellite communication services. The two companies will begin discussions toward deploying SES's Medium Earth Orbit (MEO) satellite communication service "O3b mPOWER" (*2) in Japan.SES provides multi-orbit connectivity services worldwide, supporting applications ranging from media distribution to high-performance connectivity for aviation, maritime, government, and enterprise sectors. SES's "O3b mPOWER" is a MEO satellite communication network that delivers high-throughput, low-latency, and secure connectivity with predictable performance. A key strength of the service is its ability to dynamically allocate the required capacity to mission-critical applications and areas with high communication demand. Sharp has been developing flat-panel satellite communication user terminals (*3) compatible with SES's "O3b mPOWER". These terminals leverage Sharp's core communication technologies and compact, lightweight design expertise cultivated through smartphone development.Sharp will collaborate with SES to combine SES's satellite connectivity network with Sharp's advanced communication technologies and user terminals, with the aim of exploring the provision of satellite services in Japan. The collaboration will focus on industrial use cases in areas such as maritime and mountainous regions, where terrestrial networks—such as cellular—are unreliable or unavailable. Potential use cases include enabling connectivity for heavy machinery and equipment in remote locations and managing the operations of autonomous vehicles. Through this initiative, Sharp aims to provide end-to-end solutions, spanning equipment sales, system deployment, and ongoing operations, to support dependable connectivity in such environments.Comment from Jean-Philippe Gillet,President, Fixed Vertical, SES S.A."Japan is a key innovation market with growing demand for high-performance connectivity beyond terrestrial networks. Through our collaboration with Sharp, we are bringing together MEO capabilities and advanced terminal innovation to enable scalable connectivity across key mobility and industrial segments. Together, we are committed to developing the services and technologies needed to support these use cases and to drive the continued expansion of the MEO market in Japan."Comment from Shigeru Kobayashi,Executive Officer, Co-COO and Head of Smart Workplace Business Group, Sharp Corporation"The memorandum of understanding with SES marks an important step that will accelerate our efforts toward building next-generation communications environments. At Sharp, we aim to open up the future for people by integrating AI into all aspects of how people live and work. Achieving this vision requires a reliable communications environment available anywhere. By combining SES's high-performance and reliable satellite communications infrastructure with Sharp's advanced satellite user terminals, as well as our expertise in communications technologies, we will drive this initiative with steady progress."*1 An operator that owns and operates satellites to provide communication services globally. Headquarters: Betzdorf, Luxembourg; CEO: Adel Al-Saleh.*2 SES's MEO satellites orbit at an altitude of approximately 8,000 km. Compared to Geostationary Earth Orbit (GEO) at approximately 36,000 km, MEO offers significantly lower communication latency. Compared to Low Earth Orbit (LEO) at altitudes below 2,000 km, MEO provides stable coverage over wide areas. This enables reliable connectivity even in remote locations and challenging environments.*3 A terminal that integrates a flat-panel antenna—thin, lightweight, and flat in form, unlike conventional parabolic antennas—with modem functionality. It offers excellent installability and portability.- This development is supported by funding from the National Institute of Information and Communications Technology (NICT). (Project ID: JPJ012368G50501)About SharpFor more than 110 years, Sharp Corporation has been developing pioneering, world‑first and industry-first products and technologies primarily in electronics. Based on its business creed "Sincerity and Creativity" the company has established its corporate slogan "In step with your future." and aims to create New Cultures through innovative products and services in every aspect of how people live and work. For more information, please visit: https://global.sharp/ Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Multi Meter (illustrative image)TOKYO, June 30, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that its all-new Pajero cross-country SUV, scheduled for global debut this autumn, is engineered to deliver authentic off-road performance that enables safe, secure and comfortable driving across various weather and road conditions. Symbolizing this capability, the model features the Multi Meter, a digital triple meter display that pays homage to an iconic feature popularized in previous generations.Designed to enhance the enjoyment of off-road driving, the Multi Meter on the all-new Pajero provides a wide range of information, including altitude, compass heading, ambient temperature, vehicle pitch and roll angles, and left-right torque distribution. These features allow drivers to monitor constantly changing driving conditions and vehicle dynamics in real time.Whether navigating steep inclines, winding mountain roads, narrow and rugged forest trails, uneven rocky terrain or muddy conditions after heavy rain, the system displays real-time information that helps drivers maintain confidence and control across diverse natural environments around the world.On the dedicated website for the all-new Pajero, Mitsubishi Motors has released a promotional video titled "The Pajero* is ready to write its next chapter." The video highlights the evolution of the Multi Meter - inherited and refined from earlier models - and showcases the vehicle’s ability to inspire a spirit of challenge, ignite a sense of adventure, and invite drivers to explore.Special website for the all-new Pajerohttps://www.mitsubishi-motors.co.jp/global/en/lineup/pajero/teaser/(Open in a new window)* Known as the Montero in some markets Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Nagasaki City East PlantTOKYO, June 30, 2026 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of Mitsubishi Heavy Industries (MHI) Group, has completed the rebuilding of the East Waste-to-Energy Plant in Toishimachi, Nagasaki City as part of a contract received from the Nagasaki Municipal Government in 2022. The plant has been in full operation since June 16.This rebuilding work was carried out due to the superannuation of the previous facility. Under the DBO(1) contract, operation and maintenance services at the plant will be performed over a period of 20 years by Nagasaki Higashi Eco-Creation Co., Ltd., a Special Purpose Company (SPC) created with investment(2) from MHIEC and MHI Group's Jukan Operation Co., Ltd. (President: Tatsusaburo Fujiwara; Headquarters: Kozen-machi, Nagasaki City; hereinafter JKO).The plant comprises two stoker-type incinerators(3) with a processing capacity of 105 tons per day (tpd) each, providing a total waste processing capacity of 210 tpd, and related equipment, delivering a power generating capacity of 4,940 kW through steam turbine power generating equipment. Heat energy generated during waste processing will be used for high-efficiency power generation and to supply high-temperature water to the nearby Nagasaki Higashi Park Community Facility. By maximizing use of energy, the plant will contribute to the advancement of Nagasaki's quest to be a "zero carbon city."MHIEC took over MHI's waste treatment plant business in 2008, acquiring the technological development capabilities in environmental systems and broad-ranging expertise in the construction and operation of waste management facilities both in Japan and overseas that MHI honed over many years. A strength of this company is its ability to propose total solutions from construction to operation based on its extensive track record. Going forward, MHIEC will continue to proactively make proposals to extend the life of existing waste treatment facilities, take measures against global warming, and reduce lifecycle costs (LCC) such as maintenance and management costs to contribute to the decarbonization of energy through the collection of energy from waste.(1) Under a DBO (design, build, operate) contract, a local agency or other public body procures necessary funding and entrusts a facility's design, construction and operation responsibilities to a private company while retaining its ownership.(2) MHIEC holds an 85% stake in the company, and JKO the remaining 15%(3) A stoker-type incinerator injects air from beneath heat-resistant fire grates, mixing the waste and other material by pushing it up, and allowing for efficient incineration. It is the most common system used for municipal solid waste.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com